Terumo (OTCMKTS:TRUMY) Hits New 12-Month Low – Time to Sell?

Terumo Corp. (OTCMKTS:TRUMY)’s stock price hit a new 52-week low during mid-day trading on Monday . The stock traded as low as $14.03 and last traded at $14.5450, with a volume of 11905 shares trading hands. The stock had previously closed at $14.93.

Terumo Stock Down 2.2%

The firm has a 50-day moving average of $15.74 and a two-hundred day moving average of $16.87. The firm has a market cap of $21.62 billion, a price-to-earnings ratio of 24.34 and a beta of 0.75. The company has a current ratio of 2.51, a quick ratio of 1.46 and a debt-to-equity ratio of 0.07.

Terumo (OTCMKTS:TRUMY) last issued its quarterly earnings results on Wednesday, November 12th. The company reported $0.16 EPS for the quarter, hitting the consensus estimate of $0.16. Terumo had a return on equity of 9.39% and a net margin of 12.35%.The company had revenue of $1.86 billion for the quarter, compared to the consensus estimate of $1.75 billion.

Terumo Company Profile

Terumo Corporation (OTCMKTS: TRUMY) is a Japan-based medical technology company that develops, manufactures and markets a broad range of healthcare products for hospitals, clinics and blood centers. Its businesses encompass cardiovascular systems, general hospital products and blood management and cell technologies, supplying devices used in interventional and surgical procedures as well as everyday clinical care. Terumo sells consumables and capital equipment intended to support patient care across acute and ambulatory settings.

Key product categories include vascular access and interventional devices (such as guidewires, catheters and delivery systems), cardiac and cardiopulmonary surgical equipment, infusion therapy products (including infusion pumps and disposables), syringes and blood bags.